

UK/Ireland scientific team researching human health expands academic links with 4th lab in Poland

*Contract research organisation (CRO)
Transpharmation researches neurological
and psychiatric health conditions, sleep,
pain, cancer and depression and anxiety*



LONDON, UNITED KINGDOM, February 8, 2021 /EINPresswire.com/ -- A UK and Ireland-based team of scientists

researching human neurological and psychiatric health conditions is strengthening links with academia by opening a fourth laboratory in Poland – just months after announcing a further expansion in the UK.



This will be the third university where we have established a pre-clinical base; being close to scientific leaders within a respected veterinary school will be of exponential benefit to human health.”

Dr Mark Duxon

As well as marking a further growth for contract research organisation [Transpharmation](#), the expansion also makes Transpharmation Poland the very first company to co-locate alongside University of Warmia and Mazury in Olsztyn.

The news comes two months after the announcement that Transpharmation is to open an additional laboratory at the science park Discovery Park in Kent, England – adding to its current footprint at the Royal Veterinary College (RVC) and The London Bioscience Innovation Centre in London, England, and Trinity College Institute of Neuroscience

(TCIN) in Dublin, Ireland.

The new laboratory in Poland also marks a personal milestone for Head of Operations Dr Ewa Sokolowska, who herself completed her undergraduate degree at the university. She has been overseeing pre-clinical projects at Transpharmation Ireland in Dublin for the last four years, working on behavioural pharmacology – the effects of drugs on behaviour.

Transpharmation CEO [Mark Duxon](#) said: “Poland, and especially the University, was the obvious

choice for this next stage in Transpharmation's development. This will be the third university where we have established a pre-clinical base; we know being close to scientific leaders within what is a respected veterinary school will be of exponential benefit to research on human health.

"We see Poland and the surrounding countries rising within the biotechnology and drug-discovery sector, with pharmaceutical companies moving or expanding to develop new technologies and focus on novel treatments to tackle neurodegenerative, autoimmune, cancer and other diseases affecting us all," he said. "We feel, with Transpharmation's track record and individual professional experiences and publication record, we can contribute to understanding in these important areas.

"In addition, with travel restrictions ebbing and flowing as we deal with the effects of Covid, having laboratories within mainland Europe, Ireland and England will give our US and Canadian partners flexible options in the future; while Poland becomes our primary centre for neuropsychiatric disorders, having our other centres means we can still support our client's pre-clinical testing across the Transpharmation network as local restrictions on movements change."

The creation of Transpharmation Poland will also create new jobs and new career options for students and senior scientists from the co-located veterinary school. Transpharmation is seeking a senior scientist and a research assistant in Poland in the first instance, establishing the laboratory as Transpharmation's primary centre for neuropsychiatric disorders.



Transpharmation is expanding again, by opening a fourth laboratory at the University of Warmia and Mazury in Olsztyn, Poland



Dr Ewa Sokolowska is returning to Poland and her alma mater university to establish the first commercial CRO on site

Dr Sokolowska said: "Following four years at Transpharmation Ireland, I now have this exciting challenge of establishing a new Transpharmation unit at my alma mater University of Warmia and Mazury in Olsztyn, at one of the best veterinary medicine faculties in Poland. I strongly believe that deep veterinary knowledge from academia and extensive neuroscience experience will open a completely new opportunity and benefits for research aimed at improving human health."

Transpharmation, which marked its 10th anniversary in 2020, provides research experiments, expertise, and data to show how potential new medicines might interact with the body and possess the ability to treat human diseases.

It has more than 100 clients internationally, already working from its England-based pain/cognition, sleep, and epilepsy centre of expertise at Discovery Park in Kent, The London Bioscience Innovation Centre and the Royal Veterinary College in London; and its neuroinflammation and molecular endpoints centre Trinity College Institute of Neuroscience, Dublin.

Transpharmation is led by CEO Dr Mark Duxon and Chief Scientific Officer [Dr Neil Upton](#). Both Dr Upton and Dr Duxon consolidated their early careers with industry-leader GlaxoSmithKline, with Dr Duxon leading the firm's Singapore research and development team looking at central nervous system disease and Dr Upton leading advanced clinical programmes. Dr Upton is the author of more than 200 scientific publications and holds various patents and non-commercial investigational new drug (IND) awards.

Ends

Notes to editors

Transpharmation is a contract research organisation (CRO) established 10 years ago by Dr Neil Upton and Dr Mark Duxon and continues to be led by scientists. Recognised by drug developers worldwide for researching and delivering life-changing medicines, science will always remain our passion.

Transpharmation provides CRO services for the following research areas:

- Pain
- Neuropathic pain
- Alzheimer's Disease
- Depression/anxiety
- Schizophrenia
- Inflammatory pain
- Cognitive disorders

- Multifocal motor neuropathy (MMN)
- Molecular Biomarkers
- Sleep/wake
- EEG (brain activity patterns)
- Cancer and chemotherapy
- Neuroinflammation

Press office

Transpharmation

+44 7729 284074

nicola@nbthinks.com

This press release can be viewed online at: <https://www.einpresswire.com/article/535269612>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.